Compared to the nonrecurrence group, the recurrence group had significantly larger proportions of patients with MRE11 positive cells > 50% (85.29%), breast cancer stage II/III (94.12%), age ≥ 52 years (67.65%), tumor size ≥ 2.4 cm (67.65%), LN metastasis (58.82%), negative expression of ER (58.82%), negative expression of PR (64.71%), triple negative breast cancer (35.29%), RT (79.41%), and no-HT treatment (61.76%). This evidence concerns the gene PGR and breast carcinoma.